Macrogenics Inc (MGNX)
4.10
-0.20
(-4.65%)
USD |
NASDAQ |
Jul 02, 16:00
4.11
+0.01
(+0.24%)
After-Hours: 06:00
Macrogenics SG&A Expense (TTM): 53.37M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 53.37M |
December 31, 2023 | 52.19M |
September 30, 2023 | 53.30M |
June 30, 2023 | 56.25M |
March 31, 2023 | 56.22M |
December 31, 2022 | 58.95M |
September 30, 2022 | 60.86M |
June 30, 2022 | 62.67M |
March 31, 2022 | 64.23M |
December 31, 2021 | 63.01M |
September 30, 2021 | 59.99M |
June 30, 2021 | 52.56M |
March 31, 2021 | 47.54M |
December 31, 2020 | 42.74M |
September 30, 2020 | 42.07M |
June 30, 2020 | 44.17M |
March 31, 2020 | 46.08M |
December 31, 2019 | 46.06M |
September 30, 2019 | 44.72M |
June 30, 2019 | 42.47M |
March 31, 2019 | 41.48M |
December 31, 2018 | 40.50M |
Date | Value |
---|---|
September 30, 2018 | 38.36M |
June 30, 2018 | 37.18M |
March 31, 2018 | 34.43M |
December 31, 2017 | 32.65M |
September 30, 2017 | 33.48M |
June 30, 2017 | 32.30M |
March 31, 2017 | 31.16M |
December 31, 2016 | 29.83M |
September 30, 2016 | 27.31M |
June 30, 2016 | 26.11M |
March 31, 2016 | 24.22M |
December 31, 2015 | 22.76M |
September 30, 2015 | 20.90M |
June 30, 2015 | 18.55M |
March 31, 2015 | 17.35M |
December 31, 2014 | 15.93M |
September 30, 2014 | 14.84M |
June 30, 2014 | 13.15M |
March 31, 2014 | 10.51M |
December 31, 2013 | 11.09M |
September 30, 2013 | 10.87M |
June 30, 2013 | 10.40M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
42.07M
Minimum
Sep 2020
64.23M
Maximum
Mar 2022
53.00M
Average
53.30M
Median
Sep 2023
SG&A Expense (TTM) Benchmarks
Moderna Inc | 1.518B |
Allurion Technologies Inc | 88.24M |
Novavax Inc | 443.21M |
Viking Therapeutics Inc | 37.46M |
Verrica Pharmaceuticals Inc | 59.32M |